Despite efforts to curb nicotine use, 8.1 million adults in the United States use e-cigarettes. Notably, the majority of nicotine-containing e-cigarette users report wanting to quit in the near future, yet there is a dearth of research surrounding intervention efforts. Cannabidiol (CBD) has potential to facilitate e-cigarette quit attempts by decreasing withdrawal symptom intensity and anxiety during nicotine e-cigarette abstinence.
Methods:
This study employed an open-label, crossover design (n=20) to test the hypothesis that among daily nicotine-containing e-cigarette users, oral administration of 320 mg CBD would reduce self-reported nicotine withdrawal severity and state anxiety following a 4-h e-cigarette abstinence period compared to withdrawal and anxiety reported after abstinence in the absence of CBD.
Results:
After controlling for participants' positive CBD expectancies, results were consistent with hypotheses, suggesting CBD reduced both nicotine withdrawal symptom severity and state anxiety during e-cigarette abstinence.
Conclusion:
These preliminary findings suggest testing the impact of CBD on e-cigarette cessation attempts is warranted.
Get full access to this article
View all access options for this article.
References
1.
PalmerAM, SmithTT, NahhasGJ, et al.Interest in quitting e-cigarettes among adult e-cigarette users with and without cigarette smoking history. JAMA Netw Open, 2021; 4(4):e214146.
2.
SanchezS, KaufmanP, PelletierH, et al.Is vaping cessation like smoking cessation? A qualitative study exploring the responses of youth and young adults who vape e-cigarettes. Addict Behav, 2021; 113:106687.
3.
HughesJR, PetersEN, CallasPW, et al.Withdrawal symptoms from e-cigarette abstinence among former smokers: A pre-post clinical trial. Nic Tobacco Res, 2020; 22(5):734–739; doi: 10.1093/ntr/ntz129
4.
HughesJR, PetersEN, CallasPW, et al.Withdrawal symptoms from e-cigarette abstinence among adult never-smokers: A pilot experimental study. Nic Tobacco Res, 2020; 22(5):740–746; doi: 10.1093/ntr/ntz169
5.
SahrM, KelshS, BlowerN, et al.Pilot study of electronic nicotine delivery systems (ENDS) cessation methods. Pharmacy, 2021; 9(1):21.
6.
CamposAC, MoreiraFA, GomesFV, et al.Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Phil Trans, 2012; 3 67(1607):3364–3378; doi: 10.1098/rstb.2011.0389
7.
ChyeY, ChristensenE, SolowijN, et al.The endocannabinoid system and cannabidiol's promise for the treatment of substance use disorder. Front Psych, 2019; 10(63):1–12; doi: 10.3389/fpsyt.2019.00063
8.
HillAJ, WilliamsCM, WhalleyBJ, et al.Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharma Thera, 2012; 133(1):79–97; doi: 10.1016/j.pharmthera.2011.09.002
9.
TaylorL, GidalB, BlakeyG, et al.A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs, 2018; 32:1053–1067; doi: 10.1007/s40263-018-0578-5
10.
ChesneyE, OliverD, GreenA, et al.Adverse effects of cannabidiol: A systematic review and meta-analysis of randomized clinical trials. Neuropsychopharm, 2020; 45(11):1799–1806; doi: 10.1038/s41386-020-0667-2
11.
SchoedelKA, SzetoI, SetnikB, et al.Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy Behav, 2018; 88:162–171; doi: 10.1016/j.yebeh.2018.07.027
12.
NavarreteF, García-GutiérrezMS, GasparyanA, et al.Role of cannabidiol in the therapeutic intervention for substance use disorders. Front Pharma, 2021; 12:626010.
13.
ShraderSH, TongYG, DuffMB, et al.Involvement of dopamine receptor in the actions of non-psychoactive phytocannabinoids. Biochem Biophys Res Comm, 2020; 533(4):1366–1370.
14.
SmithLC, TieuL, SuhandynataRT, et al.Cannabidiol reduces withdrawal symptoms in nicotine-dependent rats. Psychopharm, 2021; 238(8):2201–2211; doi: 10.1007/s00213-021-05845-4
15.
ZuardiAW, RodriguesNP, SilvaAL, et al.Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharma, 2017; 8:259; doi: 10.3389/fphar.2017.00259
16.
LinaresIM, ZuardiAW, PereiraLC, et al.Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Brazil J Psych, 2019; 41(1):9–14; doi: 10.1590/1516-4446-2017-0015
17.
BergamaschiMM, QueirozRH, ChagasMH, et al.Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharm, 2011; 36(6):1219–1226; doi: 10.1038/npp.2011.6
18.
MorganJA, DasRK, JoyeA, et al.Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings. Add Behav, 2013; 38(9):2433–2436; doi: 10.1016/j.addbeh.2013.03.011
19.
HindochaC, FreemanTP, GrabskiM, et al.Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. Addiction, 2018; 113(9):1696–1705; doi: 10.1111/add.14243
20.
HughesJR, HatsukamiD. Signs and symptoms of tobacco withdrawal. Arch Gen Psych, 1986; 43(3):289–294.
21.
ZvolenskyMJ, BernsteinA. Cigarette smoking and panic psychopathology. Curr Direct Psych Sci, 2005; 14(6):301–305; doi: 10.1111/j.0963-7214.2005.00386.x
22.
PiperME, CookJW, SchlamTR, et al.Anxiety diagnoses in smokers seeking cessation treatment: Relations with tobacco dependence, withdrawal, outcome and response to treatment. Addiction, 2011; 106(2):418–427; doi: 10.1111/j.1360-0443.2010.03173.x
23.
JohnsonKA, FarrisSG, SchmidtNB, et al.Panic attack history and anxiety sensitivity in relation to cognitive-based smoking processes among treatment-seeking daily smokers. Nic Tobacco Res, 2013; 15(1):1–10. doi: 10.1093/ntr/ntr332
24.
BakhshaieJ, ZvolenskyMJ, LangdonKJ, et al.Reduction of anxiety sensitivity in relation to nicotine withdrawal symptoms during smoking cessation: An examination among successful quitters. Cog Behav Ther, 2018; 47(4):301–314; doi: 10.1080/16506073.2017.1395907
25.
ZvolenskyMJ, GareyL, AllanNP, et al.Effects of anxiety sensitivity reduction on smoking abstinence: An analysis from a panic prevention program. J Cons Clin Psych, 2018; 86(5):474–485; doi: 10.1037/ccp0000288
26.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. American Psychiatric Association: Washington, DC, USA; 2013.
27.
TolinDF, GilliamC, WoottonBM, et al.Psychometric properties of a structured diagnostic interview for DSM-5 anxiety, mood, and obsessive-compulsive and related disorders. Assessment, 2016; 25(1):1–11; doi: 10.1177/1073191116638410
28.
SpielbergerCD, GorsuchRL, LusheneR, et al.Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press: Palo Alto, CA, USA; 1983.
29.
ZvolenskyMJ, MayorgaNA, GareyL. Worry, anxiety sensitivity, and electronic cigarettes among adults. Psych Res, 2018; 269:321–327.
30.
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available from: https://www.R-project.org/ [Last accessed: August15, 2020].
31.
GournayL.Innovations in e-Cigarette Cessation Intervention. March 17, 2021. Available from: https://doi.org/10.17605/OSF.IO/QG52M [Last accessed: April25, 2023].
32.
MasatakaN. Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Front Psych, 2019; 10:2466.
33.
FieldAP, WrightDB. A primer on using multilevel models in clinical and experimental psychopathology research. J Exper Psychopathol, 2011; 2(2):271–293; doi: 10.5127/jep.013711
34.
EichhammerP, JohannM, KharrazA, et al.High-frequency repetitive transcranial magnetic stimulation decreases cigarette smoking. J Clin Psych, 2003; 64(8):951–953.
35.
PattersonF, JepsonC, StrasserAA, et al.Varenicline improves mood and cognition during smoking abstinence. Bio Psych, 2008; 65(2):144–149; doi: 10.1016/j.biopsych.2008.08.028
36.
ChoiK, ForsterJ. Characteristics associated with awareness, perceptions, and use of electronic nicotine delivery systems among young us midwestern adults. Am J Public Health, 2013; 103:556–561; doi: 10.2105/AJPH.2012.300947
37.
SutfinEL, McCoyTP, MorrellHE, et al.Electronic cigarette use by college students. Drug Alcohol Depend, 2013; 131(3):214–221.
38.
St. Helen G, Havel C, Dempsey DA, et al. Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes. Addiction, 2016; 111(3):535–544.
39.
FarsalinosKE, RomagnaG, TsiaprasD. Evaluation of electronic cigarette use (vaping) topography and estimation of liquid consumption: Implications for research protocol standards definition and for public health authorities' regulation. Int J Environ Res Public Health, 2013; 10(6):2500–2514; doi: 10.3390/ijerph10062500
40.
SpinellaTC, StewartSH, NauglerJ, et al.Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: A randomized crossover study. Psychopharm, 2021; 238(7):1965–1977.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
